| アブストラクト | Catatonia is characterized by psychomotor alterations and reduced contact with the environment. Initially linked to schizophrenia, it also occurs in mood disorders or organic conditions. In children, catatonia remains poorly delineated, despite dramatically increasing the risk of premature death. As data on pediatric drug-induced catatonia bears many uncertainties, we aimed to characterize its age-dependent patterns, using real-world data from the WHO safety database (VigiBase(R)).VigiBase(R) was queried for all reports of catatonia registered up to December 8th 2022. Reports involving patients <18 years were classified into 3 groups: </=23 months, 2-11 years, and 12-17 years. Disproportionality analyses relied on the Reporting Odds Ratio (ROR), and the positivity of the lower end of the 95% confidence interval of the Information Component (IC) was required to suspect a signal. Catatonia was evoked in 421 pediatric reports. In infants, vaccines were leading. In children, the main signals involved haloperidol (ROR 104.3; 95% CI 45.6-238.5), ondansetron (ROR 40.5; 95% CI 16.5-99.5), and ciclosporin (ROR 27.4; 95% CI 13.8-54.1). In adolescents, chlorpromazine (ROR 199.1; 95% CI 134.8-294.1), benzatropine (ROR 193; 95% CI 104.1-361.6), and olanzapine (ROR 135.7; 95% CI 104.6-175.9) reached the highest RORs. In infants, catatonia was related to vaccines, it was ascribed to multiple drugs in children, and mainly to psychotropic drugs in adolescents. Less suspected drugs, such as ondansetron, were highlighted. Despite limitations inherent in spontaneous reporting systems, this study supports that a careful anamnesis is warranted to separate catatonia associated with medical conditions from drug-induced catatonia in pediatric patients. |
|---|
| ジャーナル名 | European child & adolescent psychiatry |
|---|
| Pubmed追加日 | 2023/6/13 |
|---|
| 投稿者 | Merino, Diane; Gerard, Alexandre O; Lavrut, Thibaud; Askenazy, Florence; Thummler, Susanne; Montastruc, Francois; Drici, Milou-Daniel |
|---|
| 組織名 | Department of Psychiatry, University Hospital of Nice, Nice, France.;Department of Pharmacology and Pharmacovigilance Center of Nice, University;Hospital Center of Nice, Nice, France.;Department of Child and Adolescent Psychiatry, Children's Hospitals of Nice,;CHU-Lenval Nice, Nice, France.;CoBTek Laboratory, Universite Cote d'Azur, 06000, Nice, France.;Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and;Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital,;Toulouse, France.;Hospital Center of Nice, Nice, France. pharmacovigilance@chu-nice.fr. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37308606/ |
|---|
